Trans-arterial chemoembolization as a therapy for liver tumours: New clinical developments and suggestions for combination with angiogenesis inhibitors

Critical Reviews in Oncology/Hematology

Volumn 80, Issue 1, 2011, Pages 40-53

  Gadaleta, C Damiano ^a   Ranieri, Girolamo ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

Angiogenesis; Angiogenesis inhibitors; DC Beads; Doxorubicin; HepaSphere; Irinotecan; Liver tumours; Trans arterial chemoembolization (TACE); VEGF

Indexed keywords

2 ACRYLAMIDO 2 METHYLPROPANE SULFONIC ACID; ACLARUBICIN; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CARMUSTINE; CISPLATIN; DOXORUBICIN; DRUG CARRIER; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GELATIN SPONGE; GEMCITABINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; IODINATED POPPYSEED OIL; IRINOTECAN; MICROSPHERE; MITOMYCIN C; OXALIPLATIN; POLYVINYL ALCOHOL; SORAFENIB; STEEL; SULFONIC ACID DERIVATIVE; SUNITINIB; THIOTEPA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; BILE DUCT CARCINOMA; BREAST CANCER; CHEMOEMBOLIZATION; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DIGESTIVE SYSTEM CANCER; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG RESPONSE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HEPATITIS; HISTOPATHOLOGY; HUMAN; KIDNEY CANCER; LIVER CANCER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER METASTASIS; MELANOMA; MULTIPLE CYCLE TREATMENT; NEUROENDOCRINE TUMOR; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RECOMMENDED DRUG DOSE; REVIEW; UVEA MELANOMA;

ANGIOGENESIS INHIBITORS; ANIMALS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; BREAST NEOPLASMS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CHOLANGIOCARCINOMA; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; ENDOCRINE GLAND NEOPLASMS; FEMALE; HUMANS; KIDNEY NEOPLASMS; LIVER NEOPLASMS; MALE; MELANOMA; MICROSPHERES; UVEAL NEOPLASMS;

EID: 80053132166     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2010.10.005     Document Type: Review

References (88)

1. Gadaleta C.D., Catino A., Ranieri G., Armenise F., Console G., Mattioli V. Hypoxic stop-flow perfusion with mitomycin-C in the treatment of multifocal liver metastases. Usefulness of a vascular arterial stent to prevent iatrogenic lesions of the hepatic arterial wall. J Exp Clin Cancer Res 2003, 4:203-206.
2. Kettenbach J., Stadler A., Katzler I.V., et al. Drug-loaded microspheres for the treatment of liver cancer: review of current results. Cardiovasc Intervent Radiol 2008, 3:468-476.
3. Miyayama S., Matsui O., Yamashiro M., et al. Visualization of hepatic lymphatic vessels during transcatheter arterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol 2007, 18(9):1111-1117.
4. Nakakuma K., Tashiro S., Hiraoka T., et al. Studies on anticancer treatment with an oily anticancer drug injected into the ligated feeding hepatic artery for liver cancer. Cancer 1983, 52:2193-2200.
5. Kan Z., McCuskey P.A., Wright K.C., Wallace S. Role of Kupffer cells in iodized oil embolization. Invest Radiol 1994, 29:990-993.
6. Mabed M., Esmaeel M., El-Khodary T., Awad M., Amer T. A randomized controlled trial of transcatheter arterial chemoembolization with lipiodol, doxorubicin and cisplatin versus intravenous doxorubicin for patients with unresectable hepatocellular carcinoma. Eur J Cancer Care 2009, 5:492-499.
7. Nakamura H., Hashimoto T., Oi H., Sawada S. Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 1989, 170:783-786.
8. Sakaguchi H., Uchida H., Nishimura Y., Guo Q.Y., Yoshimura H., Ohishi H. Pharmacokinetic study of adriamycin in the emulsion mixed with Lipiodol-difference resulting from composition and methods of preparation, and behavior after mesenteric arterial injection in rat. Gan To Kagaku Ryoho 1991, 18:1349-1355.
9. Raoul J.L., Heresbach D., Bretagne J.F., et al. Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. Cancer 1992, 70:585-590.
10. Marelli L., Stigliano R., Triantos C., et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007, 30:6-25.
11. Shin S.W. The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma. Korean J Radiol 2009, 10(5):425-434.
12. Makuuchi M., Sukigara M., Mori T., et al. Bile duct necrosis: complication of transcatheter hepatic arterial embolization. Radiology 1985, 156:331-334.
13. Coldwell D.M., Stokes K.R., Yakes W.F. Embolotherapy: agents, clinical applications, and techniques. Radiographics 1994, 14:623-643.
14. Lewis A.L., Gonzalez M.V., Lloyd A.W., et al. DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol 2006, 17(2):335-342.
15. Lewis A.L. DC Bead: a major development in the toolbox for the interventional oncologist. Expert Rev Med Devices 2009, 4:389-400.
16. Binaschi M., Bigioni M., Cipollone A., et al. Anthracyclines: selected new developments. Curr Med Chem Anticancer Agents 2001, 1:113-130.
17. Sadick M., Haas S., Loehr M., et al. Application of DC beads in hepatocellular carcinoma: clinical and radiological results of a drug delivery device for transcatheter superselective arterial embolization. Onkologie 2010, 33:31-37.
18. Ramesh M., Ahlawat P., Srinivas N.R. Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives. Biomed Chromatogr 2010, 24:104-123.
19. Kaiser J., Thiesen J., Krämer I. Stability of irinotecan-loaded drug eluting beads (DC Bead) used for transarterial chemoembolization. J Oncol Pharm Pract 2010, 16:53-61.
20. Hong K., Khwaja A., Liapi E., Torbenson M.S., Georgiades C.S., Geschwind J.F. New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res 2006, 12:2563-2567.
21. Lewis A.L., Taylor R.R., Hall B., Gonzalez M.V., Willis S.L., Stratford P.W. Pharmacokinetic and safety study of doxorubicin-eluting beads in a porcine model of hepatic arterial embolization. J Vasc Interv Radiol 2006, 8:1335-1343.
22. de Luis E., Bilbao J.I., de Ciércoles J.A., Martínez-Cuesta A., de Martino Rodríguez A., Lozano M.D. In vivo evaluation of a new embolic spherical particle (HepaSphere) in a kidney animal model. Cardiovasc Intervent Radiol 2008, 2:367-376.
23. Eyol E., Boleij A., Taylor R.R., Lewis A.L., Berger M.R. Chemoembolisation of rat colorectal liver metastases with drug eluting beads loaded with irinotecan or doxorubicin. Clin Exp Metastasis 2008, 25(3):273-282.
24. Laurent A., Velzenberger E., Wassef M., Pelage J., Lewis A. Do microspheres with narrow or standard size distributions localize differently in vasculature? An experimental study in sheep kidney and uterus. J Vasc Interv Radiol 2008, 12:1733-1739.
25. Alberts S.R., Wagman L.D. Chemotherapy for colorectal cancer liver metastases. Oncologist 2008, 10:1063-1073.
26. Wasser K., Giebel F., Fischbach R., Tesch H., Landwehr P. Transarterial chemoembolization of liver metastases of colorectal carcinoma using degradable starch microspheres (Spherex): personal investigations and review of the literature. Radiologe 2005, 45(7):633-643.
27. Aliberti C., Tilli M., Benea G., Fiorentini G. Trans-arterial chemoembolization (TACE) of liver metastases from colorectal cancer using irinotecan-eluting beads: preliminary results. Anticancer Res 2006, 26:3793-3795.
28. Fiorentini G., Aliberti C., Turrisi G., et al. Intraarterial hepatic chemoembolization of livermetastases from colorectal cancer adopting irinotecan-eluting beads: results of a phase II clinical study. In Vivo 2007, 6:1085-1091.
29. Fiorentini G., Aliberti C., Benea G., et al. TACE of liver metastases from colorectal cancer adopting irinotecan-eluting beads: beneficial effect of palliative intra-arterial lidocaine and post-procedure supportive therapy on the control of side effects. Hepatogastroenterology 2008, 88:2077-2082.
30. Poggi G., Quaretti P., Minoia C., et al. Transhepatic arterial chemoembolization with oxaliplatin-eluting microspheres (OEM-TACE) for unresectable hepatic tumors. Anticancer Res 2008, 28(6B):3835-3842.
31. Carrasco C.H., Wallace S., Charnsangavej C., Papadopoulos N.E., Patt Y.Z., Mavligit G.M. Treatment of hepatic metastases in ocular melanoma. Embolization of the hepatic artery with polyvinyl sponge and cisplatin. JAMA 1986, 22:3152-3154.
32. Mavligit G.M., Charnsangavej C., Carrasco C.H., Patt Y.Z., Benjamin R.S., Wallace S. Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. JAMA 1988, 260(7):974-976.
33. Agarwala S.S., Panikkar R., Kirkwood J.M. Phase I/II randomized trial of intrahepatic arterial infusion chemotherapy with cisplatin and chemoembolization with cisplatin and polyvinyl sponge in patients with ocular melanoma metastatic to the liver. Melanoma Res 2004, 14:217-222.
34. Patel K., Sullivan K., Berd D., et al. Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study. Melanoma Res 2005, 15:297-304.
35. Vogl T., Eichler K., Zangos S., et al. Preliminary experience with transarterial chemoembolization (TACE) in liver metastases of uveal malignant melanoma: local tumor control and survival. J Cancer Res Clin Oncol 2007, 133:177-184.
36. Fiorentini G., Aliberti C., Del Conte A., et al. Intra-arterial hepatic chemoembolization (TACE) of liver metastases from ocular melanoma with slow-release irinotecan-eluting beads. Early results of a phase II clinical study. In Vivo 2009, 23:131-137.
37. Durante C., Boukheris H., Dromain C., et al. Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma. Endocr Relat Cancer 2009, 2:585-597.
38. Roche A., Girish B.V., de Baère T., et al. Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol 2003, 1:136-140.
39. de Baere T., Deschamps F., Teriitheau C., et al. Transarterial chemoembolization of liver metastases from well differentiated gastroenteropancreatic endocrine tumors with doxorubicin-eluting beads: preliminary results. J Vasc Interv Radiol 2008, 6:855-861.
40. Diamond J.R., Finlayson C.A., Borges V.F. Hepatic complications of breast cancer. Lancet Oncol 2009, 6:615-621.
41. Li X.P., Meng Z.Q., Guo W.J., Li J. Treatment for liver metastases from breast cancer: results and prognostic factors. World J Gastroenterol 2005, 11:3782-3787.
42. Vogl T.J., Naguib N.N., Nour-Eldin N.E., Eichler K., Zangos S., Gruber-Rouh T. Transarterial chemoembolization (TACE) with mitomycin C and gemcitabine for liver metastases in breast cancer. Eur Radiol 2010, 20:173-180.
43. Nabil M., Gruber T., Yakoub D., Ackermann H., Zangos S., Vogl T.J. Repetitive transarterial chemoembolization (TACE) of liver metastases from renal cell carcinoma: local control and survival results. Eur Radiol 2008, 18:1456-1463.
44. Aljiffry M., Walsh M.J., Molinari M. Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009. World J Gastroenterol 2009, 15:4240-4262.
45. Gusani N.J., Balaa F.K., Steel J.L., et al. Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): a single-institution experience. J Gastrointest Surg 2008, 12:129-137.
46. Aliberti C., Benea G., Tilli M., Fiorentini G. Chemoembolization (TACE) of unresectable intrahepatic cholangiocarcinoma with slow-release doxorubicin-eluting beads: preliminary results. Cardiovasc Intervent Radiol 2008, 31:883-888.
47. Poggi G., Amatu A., Montagna B., et al. OEM-TACE: a new therapeutic approach in unresectable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol 2009, 29.
48. Shin S.W. The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma. Korean J Radiol 2009, 10:425-434.
49. Shen H., Agarwal D., Qi R., et al. Predictors of outcome in patients with unresectable hepatocellular carcinoma receiving transcatheter arterial chemoembolization. Aliment Pharmacol Ther 2007, 26:393-400.
50. Xiao E.H., Guo D., Bian D.J. Effect of preoperative transcatheter arterial chemoembolization on angiogenesis of hepatocellular carcinoma cells. World J Gastroenterol 2009, 15:4582-4586.
51. Leelawat K., Laisupasin P., Kiatdilokrut A., et al. The effect of doxorubicin on the changes of serum vascular endothelial growth factor (VEGF) in patients with hepatocellular carcinoma after transcatheter arterial chemoembolization (TACE). J Med Assoc Thai 2008, 91:1539-1543.
52. Malagari K., Chatzimichael K., Alexopoulou E., et al. Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovasc Intervent Radiol 2008, 31:269-280.
53. Ishida K., Hirooka M., Hiraoka A., et al. Treatment of hepatocellular carcinoma using arterial chemoembolization with degradable starch microspheres and continuous arterial infusion of 5-fluorouracil. Jpn J Clin Oncol 2008, 38:596-603.
54. Grosso M., Vignali C., Quaretti P., et al. Transarterial chemoembolization for hepatocellular carcinoma with drug-eluting microspheres: preliminary results from an Italian multicentre study. Cardiovasc Intervent Radiol 2008, 31:1141-1149.
55. Ranieri G., Patruno R., Ruggieri E., Montemurro S., Valerio P., Ribatti D. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr Med Chem 2006, 13:1845-1857.
56. Li X., Feng G.S., Zheng C.S., Zhuo C.K., Liu X. Influence of transarterial chemoembolization on angiogenesis and expression of vascular endothelial growth factor and basic fibroblast growth factor in rat with Walker-256 transplanted hepatoma: an experimental study. World J Gastroenterol 2003, 9:2445-2449.
57. Wang B., Xu H., Gao Z.Q., Ning H.F., Sun Y.Q., Cao G.W. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol 2008, 49:523-529.
58. Shim J.H., Park J.W., Kim J.H., et al. Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Sci 2008, 99:2037-2044.
59. Sergio A., Cristofori C., Cardin R., et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol 2008, 103:914-921.
60. Xiong Z.P., Yang S.R., Liang Z.Y., et al. Association between vascular endothelial growth factor and metastasis after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2004, 3:386-390.
61. Li X., Feng G.S., Zheng C.S., Zhuo C.K., Liu X. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol 2004, 10:2878-2882.
62. Liu J., Yi J. Relationship between the changes of VEGF level and dendritic cells in peripheral blood of patients with hepatocellular carcinoma after transcatheter arterial chemoembolization. J Huazhong Univ Sci Technolog Med Sci 2007, 27:58-60.
63. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390.
64. Cheng A.L., Kang Y.K., Chen Z., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10:25-34.
65. Simpson D., Keating G.M. Sorafenib: in hepatocellular carcinoma. Drugs 2008, 68:251-258.
66. Hoffmann K., Glimm H., Radeleff B.G., et al. Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794]. BMC Cancer 2008, 8:349.
67. Chao Y, Yoon J, Li C, et al. START: Study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial. 2010 Gastrointestinal Cancers Symposium.
68. Greten T.F., Korangy F., Manns M.P., Malek N.P. Molecular therapy for the treatment of hepatocellular carcinoma. Br J Cancer 2009, 100:19-23.
69. Koeberle D., Montemurro M., Samaras P., et al. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist 2010, 15:285-292.
70. Patruno R., Arpaia N., Gadaleta C.D., et al. VEGF concentration from plasma-activated platelets rich correlates with microvascular density and grading in canine mast cell tumour spontaneous model. J Cell Mol Med 2009, 13:555-561.
71. Ranieri G., Ruggieri E., Falco G., et al. Drug targets to pro-angiogenetic factors with special reference to primary peritoneal mesothelioma. Endocr Metab Immune Disord Drug Targets 2006, 6:271-277.
72. Siegel A.B., Cohen E.I., Ocean A., et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008, 26:2992-2998.
73. Hsu C.H., Yang T.S., Hsu C., et al. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br J Cancer 2010, 102:981-986.
74. Reyes DK, Vossen JA, Kamel IR, et al. Phase II trial of bevacizumab combined with transarterial chemoembolization (TACE) for hepatocellular carcinoma: initial experience at two institutions. 2010 Gastrointestinal Cancers Symposium.
75. Eisenhauer E.A., Therasse P., Bogaerts J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
76. Eberhard A., Kahlert S., Goede V., Hemmerlein B., Plate K.H., Augustin H.G. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 2000, 60:1388-1393.
77. Sun S., Schiller J.H. Angiogenesis inhibitors in the treatment of lung cancer. Crit Rev Oncol Hematol 2007, 62:93-104.
78. Lamuraglia M., Bridal S.L., Santin M., et al. Clinical relevance of contrast-enhanced ultrasound in monitoring anti-angiogenic therapy of cancer: current status and perspectives. Crit Rev Oncol Hematol 2010, 73:202-212.
79. Delbeke D. Oncological applications of FDGPET imaging. J Nucl Med 1999, 40:1706-1715.
80. Tofts P.S., Brix G., Buckley D.L., et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusible tracer: standardized quantities and symbols. J Magn Reson Imaging 1999, 10:223-232.
81. Brix G., Bahner M.L., Hoffmann U., Horvath A., Schreiber W. Regional blood flow, capillary permeability, and compartmental volumes: measurement with dynamic CT-initial experience. Radiology 1999, 210:269-276.
82. Lucidarme O., Kono Y., Corbeil J., et al. Angiogenesis: noninvasive quantitative assessment with contrast-enhanced functional US in murine model. Radiology 2006, 239:730-739.
83. Gadaleta C., Catino A., Mattioli V. Stop-flow perfusion with mitomycin-C as locoregional approach in the treatment of large-unresectable liver metastases. In Vivo 2006, 20:769-771.
84. Martin R.C., Robbins K., Tomalty D., et al. Transarterial chemoembolisation (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal cancer: an interim report. World J Surg Oncol 2009, 7:80.
85. Gadaleta C., Catino A., Ranieri G., et al. Single-step therapy feasibility and safety of simultaneous transarterial chemoembolization and radiofrequency ablation for hepatic malignancies. In Vivo 2009, 23:813-820.
86. Georgiades C.S., Hong K., Geschwind J.F. Radiofrequency ablation and chemoembolization for hepatocellular carcinoma. Cancer J 2008, 14:117-122.
87. Ranieri G., Ammendola M., Patruno R., et al. Tryptase-positive mast cells correlate with angiogenesis in early breast cancer patients. Int J Oncol 2009, 35:115-120.
88. Ranieri G., Grammatica L., Patruno R., et al. A possible role of thymidine phosphorylase expression and 5-fluorouracil increased sensitivity in oropharyngeal cancer patients. J Cell Mol Med 2007, 11:362-368.